GSK plc (GSK) — Quality & forensics
As of 2026-11-03 — refreshed nightly. Closelooknet readings from an investment research diary, not ratings or advice.
The Closelooknet module scores
- Valuation 55
- Quality 79
- Growth 38
- Balance sheet 46
- Cash quality 49
- Capital allocation 63
- Momentum 45
Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.
Financial forensics — the academic screens
Sits in the grey zone (1.81–2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.
Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.
Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.
Continue: the GSK chart & overview · the earnings record
FAQ · from the current data · as of 2026-11-03
Quick answers
What is GSK plc's Closelooknet quality reading?
The composite reads 54/100 across 7 modules, as of 2026-11-03: valuation 55, quality 79, growth 38, balance sheet 46, cash quality 49, capital allocation 63, momentum 45. Closelooknet scores are research diary readings, not ratings or investment advice.
What is GSK plc's Altman Z-Score?
2.48, which sits in the grey zone (1.81–2.99) as of 2026-11-03. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.
What is GSK plc's Piotroski F-Score?
9 of 9, as of 2026-11-03. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.
What does GSK plc's Beneish M-Score indicate?
-2.37 — below the −1.78 manipulation-risk threshold, as of 2026-11-03. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.
Related in the Closelooknet universe
then Drug Manufacturers - General, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- LLY Eli Lilly and Companyindustry
- ORNAV.HE Orion Oyj Aindustry
- ORNBV.HE Orion Oyj Bindustry
- SAN.PA Sanofi SAindustry
- AMGN Amgen Incindustry
- NVO Novo Nordisk A/Sindustry
- GILD Gilead Sciences Incindustry
- BIIB Biogen Incindustry
- SNY Sanofi ADRindustry
- ABBV AbbVie Incindustry
- PFE Pfizer Incindustry
- OGN Organon & Coindustry
- JNJ Johnson & Johnsonindustry
- BMY Bristol-Myers Squibb Companyindustry
- MRK Merck & Company Incindustry
- 002422.SHE Sichuan Kelun Pharmaceutical Co Ltdindustry
- AZN AstraZeneca PLCindustry
- CMHC.SW COSMO N NVindustry
- HALO Halozyme Therapeutics Incsector
- ONC BeOne Medicines AGsector